Obermatt
See Similar Stocks →

Flags

Financial distress

Xoma Royalty

NMQ:XOMA · US98419J2069
BiotechnologySmall

360

40
Medium confidence — indicative
Profit price—
Cash yield1
Price/Sales70
EV / Gross Profit35
Price/Book32
Return on Capital82
Return on Equity96
EBIT Margin69
Gross Profitability58

Cash truth not applicable for financial companies.

Sales growth69
Profit growth48
Reinvestment21
Price momentum58
Debt load21
Debt serviceability97
Liquidity92
Analyst ratings5
Opinion Changes5
Price Target Upside6
Market mood43
Value Creation13/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Xoma Royalty clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded1981
Employees40
Websitexoma.com
ISINUS98419J2069
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
RespiratoryNeurologyOncologyBiotechnologyDeveloper PlatformHealth CareTherapeutics

Description

XOMA Royalty Corporation (XOMA) operates as a royalty aggregator, playing a distinctive role in assisting biotech companies in achieving their goal of improving human health. The company is a royalty aggregator with a sizable portfolio of economic r…

Analysis

Middle-of-the-road

XOMA Royalty Corporation is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 13/20 on our value-creation score: creating some value.

What to watch: Some accounting patterns deserve a closer look. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
16
2026

All-time high

54

Mar 2026

All-time low

16

Jun 2026

Average rank

35

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
70
—
—
—
Price/Earnings
7
—
—
—
Price/Book
32
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
24
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Xoma Royalty with its peers
Day One Biopharmaceuticals
NSQ:DAWN
39
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Xencor
NMQ:XNCR
13
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Xenon Pharmaceuticals
NMQ:XENE
28
CountryCanada
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tharimmune
NAQ:THAR
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
PepGen
NSQ:PEPG
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Design Therapeutics
NSQ:DSGN
71
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →